22nd Century Group is to announce its full year results on 1st March, after confirming the launch of its two low-nicotine cigarettes as modified risk tobacco products, following the US Food and Drug Administration (FDA)’s marketing authorisation in December.

The New York-based company said a the pilot market launch of its VLN products, including a menthol cigarette, would begin in an unnamed “major metropolitan market”, with expansion to a full nationwide marketing and distribution launch soon after.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us